ABIONYX Pharma Provides an Update on Its Business and Cash Position for the 4th Quarter of 2024
28 2월 2025 - 3:20AM
Business Wire
- Consolidated revenue of €4.6m in 2024
- Available cash of €3.2m at December 31, 2024
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME), a next generation biopharma company dedicated to the
development of innovative biomedicines based on a recombinant
apolipoprotein apoA-1 for the treatment of the most severe
inflammatory diseases, today provides an update on its business and
its cash position as of December 31, 2024.
Selected financial information (IFRS)
m€
2024
2023
Revenue from biotech activity
0.00
0.00
Revenue from IRIS Pharma
4.55
4.64
Total revenue
4.55
4.64
Other revenue income and revenue
0.00
0.00
Total revenue income and
revenue
4.55
4.64
Cash and cash equivalents at the end of
the period
3.24
4.10
ABIONYX Pharma recorded a consolidated turnover of €4.6 million
for the 2024 financial year, which is the result of the activity of
its subsidiary IRIS Pharma, which remained stable in 2024 compared
to 2023, despite a more complicated CRO industrial context.
Regarding the biotech activity dedicated to the discovery and
development of innovative therapies aimed at improving the lives of
patients, the company did not generate any revenue during this
financial year, as the company continues to provide its bioproduct
free of charge as part of compassionate access authorization (CAA)
requests. The company continues to receive new requests for
Compassionate Access Authorization for the orphan disease LCAT from
several hospitals around the world.
Cash and cash equivalents amounted to €3.2 million at the end of
2024, compared with €4.1 million at the end of 2023.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biopharma company dedicated
to the development of innovative biomedicines for the most severe
inflammatory diseases for which there is no effective or existing
treatment, even in the rarest indications. The company accelerates
the development of breakthrough therapies thanks to in-depth
expertise in lipid science and a technological platform based on
recombinant apoA-I. ABIONYX Pharma is committed to radically
improving the results of sepsis treatments and intensive care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250227063779/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Abionyx Pharma (EU:ABNX)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
